Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan 20;23(3):1119.
doi: 10.3390/ijms23031119.

Epigenetic Modification of PD-1/PD-L1-Mediated Cancer Immunotherapy against Melanoma

Hikaru Nanamori  1 , Yu Sawada  1
Affiliations
Review

Epigenetic Modification of PD-1/PD-L1-Mediated Cancer Immunotherapy against Melanoma

Hikaru Nanamori et al. Int J Mol Sci. .

Abstract

Malignant melanoma is one of the representative skin cancers with unfavorable clinical behavior. Immunotherapy is currently used for the treatment, and it dramatically improves clinical outcomes in patients with advanced malignant melanoma. On the other hand, not all these patients can obtain therapeutic efficacy. To overcome this limitation of current immunotherapy, epigenetic modification is a highlighted issue for clinicians. Epigenetic modification is involved in various physiological and pathological conditions in the skin. Recent studies identified that skin cancer, especially malignant melanoma, has advantages in tumor development, indicating that epigenetic manipulation for regulation of gene expression in the tumor can be expected to result in additional therapeutic efficacy during immunotherapy. In this review, we focus on the detailed molecular mechanism of epigenetic modification in immunotherapy, especially anti-PD-1/PD-L1 antibody treatment for malignant melanoma.

Keywords: anti-PD-L1 antibody; anti-PD1 antibody; epigenetics; malignant melanoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Epigenetic histone modification (A) Histone modification. DNA binds to histone for gene repression, while the weak connection of DNA and histone activates gene transcription. (B) Histone binds to DNA via voltage connection, which is canceled by HAT-mediated histone acetylation. HDAC cancels the histone acetylation, leading to gene repression.
See this image and copyright information in PMC

References

    1. Sullivan A., Edlund C., Nord C.E. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect. Dis. 2001;1:101–114. doi: 10.1016/S1473-3099(01)00066-4. - DOI - PubMed
    1. Taïeb A. Skin barrier in the neonate. Pediatr. Dermatol. 2018;35:s5–s9. doi: 10.1111/pde.13482. - DOI - PubMed
    1. Kabashima K., Honda T., Ginhoux F., Egawa G. The immunological anatomy of the skin. Nat. Rev. Immunol. 2019;19:19–30. doi: 10.1038/s41577-018-0084-5. - DOI - PubMed
    1. Dainichi T., Kitoh A., Otsuka A., Nakajima S., Nomura T., Kaplan D.H., Kabashima K. The epithelial immune microenvironment (EIME) in atopic dermatitis and psoriasis. Nat. Immunol. 2018;19:1286–1298. doi: 10.1038/s41590-018-0256-2. - DOI - PubMed
    1. Sawada Y., Nakamura M., Tokura Y. Generalized fixed drug eruption caused by pazufloxacin. Acta. Derm. Venereol. 2011;91:600–601. doi: 10.2340/00015555-1132. - DOI - PubMed

MeSH terms